DelveInsight’s “Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast–2034” provides a comprehensive analysis of Ewing Sarcoma, covering historical and projected epidemiological trends as well as current and future market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Ewing Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ewing Sarcoma Market Forecast
Some of the key facts of the Ewing Sarcoma Market Report:
-
The Ewing Sarcoma market is projected to grow at a substantial CAGR during the study period (2020–2034).
-
In 2023, the United States accounted for the largest share of the Ewing sarcoma drugs market across the seven major markets (7MM), representing roughly 53%. Advancements in treatment have improved patient outcomes, with a 5-year survival rate of 70–80% for localized Ewing sarcoma, while metastatic cases show a lower survival rate of around 30–40%, depending on individual factors and treatment response.
-
According to NCCN guidelines (v2.2023), lurbinectedin is now recommended as a second-line therapy for relapsed, refractory, or metastatic Ewing sarcoma.
-
Key companies driving Ewing sarcoma therapy development include Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Eli Lilly, Bioatla, Inhibrx, and others, focusing on second-line and subsequent treatment stages. Last year, Salarius Pharmaceuticals paused patient enrollment in its Phase I/II trial of seclidemstat due to an unexpected significant adverse reaction (SUSAR). In May 2023, the FDA reviewed the application and approved the trial’s resumption.
-
In the 7MM, the United States reported the highest number of Ewing sarcoma cases, accounting for approximately 41%, while Germany had the highest incidence in the EU4 at about 15%, and Italy had the fewest. In the U.S., the 10–14 years age group represented the largest share of cases (around 30%), followed by the 15–19 years group at 26% in 2023. Males are more frequently affected than females, with an estimated 300 new male cases in the U.S. in 2023.
-
On November 12, 2024, the FDA granted Rare Pediatric Disease Designation to elraglusib (9-ING-41), a novel GSK-3β inhibitor, as a potential treatment for Ewing sarcoma patients.
-
Key Companies: Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, and others Key Therapies: Seclidemstat, ZEPZELCA (lurbinectedin), and others
-
The Ewing Sarcoma market is expected to expand significantly due to the increasing prevalence of the disease and growing awareness. The introduction of multiple-stage pipeline therapies is anticipated to transform market dynamics in the coming years.
Ewing Sarcoma Overview
Ewing sarcoma is a malignant tumor that primarily develops in bones, most commonly affecting children and adolescents, often during their teenage years. It typically involves long bones such as the femur, tibia, and humerus, as well as the pelvis, though it can occasionally arise in muscles or soft tissues. Common symptoms include bone pain, swelling, stiffness, or tenderness in the affected area.
The patient journey usually begins with persistent bone pain, swelling, or a palpable mass. Patients are often referred to an orthopedist, who recommends diagnostic imaging such as MRI, CT scans, and X-rays. After initial evaluation, patients are referred to an oncologist for treatment, and a biopsy is performed on the mass to confirm the diagnosis.
Treatment for Ewing sarcoma typically involves a multidisciplinary approach, combining surgery, chemotherapy, and radiation therapy. According to NCCN guidelines, several chemotherapy regimens are recommended for localized and metastatic cases. First-line therapies include VDC/IE (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, etoposide). For second-line treatments, NCCN suggests options such as cyclophosphamide with topotecan, irinotecan combined with temozolomide, and other regimens including vincristine, ifosfamide, carboplatin, etoposide, and lurbinectedin.
Get a Free sample for the Ewing Sarcoma Market Forecast, Size & Share Analysis Report
Ewing Sarcoma Epidemiology
The epidemiology section offers a comprehensive overview of past, present, and projected trends in the seven major markets (7MM) from 2020 to 2034. It examines the underlying factors driving both current and future trends by analyzing findings from multiple studies and insights from key opinion leaders. Additionally, the section provides an in-depth assessment of the diagnosed patient population and highlights anticipated developments in the epidemiology over the forecast period.
Ewing Sarcoma Epidemiology Segmentation:
The Ewing Sarcoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Diagnosed Prevalence of Ewing Sarcoma in Adults
-
Diagnosed Prevalence of Ewing Sarcoma in Pediatrics
-
Diagnosed Prevalence of Ewing Sarcoma by Types
-
Diagnosed Prevalence of Ewing Sarcoma by Location
-
Diagnosed Prevalence of Ewing Sarcoma by Severity
Download the report to understand which factors are driving Ewing Sarcoma epidemiology trends @ Ewing Sarcoma Epidemiology Forecast
Ewing Sarcoma Emerging Drugs
-
Seclidemstat: Salarius Pharmaceuticals
-
ZEPZELCA (lurbinectedin): Jazz Pharmaceuticals and PharmaMar
Ewing Sarcoma Therapies: Seclidemstat, ZEPZELCA (lurbinectedin), and others
Ewing Sarcoma Key Companies: Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, and others
Discover more about therapies set to grab major Ewing Sarcoma market share @ Ewing Sarcoma Treatment Landscape
Ewing Sarcoma Market Outlook
Although treatments for Ewing sarcoma—including chemotherapy, surgery, and radiation therapy—have improved survival for some patients, progress remains limited for others. Managing high-risk Ewing sarcoma and related sarcomas is particularly challenging due to the incomplete understanding of their high-risk biological features and their low incidence, which complicates the conduction of large-scale clinical trials for small patient populations and rarer sarcoma subtypes.
There is currently no standardized second-line therapy for refractory or relapsed Ewing sarcoma, though several retrospective studies have reported outcomes with conventional salvage treatments. These often include topotecan, cyclophosphamide, irinotecan, temozolomide, or high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (auto-SCT). The combination of HDC with auto-SCT has been extensively studied, and multiple retrospective and single-arm studies suggest promising outcomes for patients with high-risk or refractory disease, despite variations in conditioning regimens.
Emerging strategies under investigation include RNA interference, targeted protein degraders, and immunotherapies directed at novel tumor epitopes. Current treatment for Ewing sarcoma remains focused on chemotherapy, radiation, and surgery.
The future outlook includes the anticipated launch of new therapies, improved early patient screening, better integration of treatments in secondary and clinical care, and heightened awareness, all of which are expected to advance more effective treatment options. Nevertheless, the lack of effective therapies underscores the urgent need for progress in addressing this orphan disease. Due to its rarity, conducting clinical trials is difficult, highlighting the need for increased research efforts in this area.
Scope of the Ewing Sarcoma Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Ewing Sarcoma Companies: Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, and others
-
Key Ewing Sarcoma Therapies: Seclidemstat, ZEPZELCA (lurbinectedin), and others
-
Ewing Sarcoma Therapeutic Assessment: Ewing Sarcoma current marketed and Ewing Sarcoma emerging therapies
-
Ewing Sarcoma Market Dynamics: Ewing Sarcoma market drivers and Ewing Sarcoma market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Ewing Sarcoma Unmet Needs, KOL’s views, Analyst’s views, Ewing Sarcoma Market Access and Reimbursement
To know more about Ewing Sarcoma companies working in the treatment market, visit @ Ewing Sarcoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Ewing Sarcoma Market Report Introduction
2. Executive Summary for Ewing Sarcoma
3. SWOT analysis of Ewing Sarcoma
4. Ewing Sarcoma Patient Share (%) Overview at a Glance
5. Ewing Sarcoma Market Overview at a Glance
6. Ewing Sarcoma Disease Background and Overview
7. Ewing Sarcoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Ewing Sarcoma
9. Ewing Sarcoma Current Treatment and Medical Practices
10. Ewing Sarcoma Unmet Needs
11. Ewing Sarcoma Emerging Therapies
12. Ewing Sarcoma Market Outlook
13. Country-Wise Ewing Sarcoma Market Analysis (2020–2034)
14. Ewing Sarcoma Market Access and Reimbursement of Therapies
15. Ewing Sarcoma Market Drivers
16. Ewing Sarcoma Market Barriers
17. Ewing Sarcoma Appendix
18. Ewing Sarcoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Ewing Sarcoma Pipeline
"Ewing Sarcoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ewing Sarcoma market. A detailed picture of the Ewing Sarcoma pipeline landscape is provided, which includes the disease overview and Ewing Sarcoma treatment guidelines.
Ewing Sarcoma Epidemiology
DelveInsight's 'Ewing Sarcoma Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Ewing Sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
